RxDoctor Payments Data

Jeffrey Sponsler, MD

Neurology · Wasilla, AKNPI 1538206164

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.0% of the total across 354 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 39 manufacturers, the largest accounting for just 11.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $1,734 and has fallen 53.7% since, to $803 in 2025.

$7,765in general payments, 2019–2025

Across 354 payments — averaging $21.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$921
  • EMD Serono, Inc.$748
  • Neurocrine Biosciences, Inc.$557
  • UCB, Inc.$497
  • Novartis$471
  • SK Life Science, Inc.$436
  • plus $4K from 33 others

What the payments were for

  • Speaking & faculty fees$501%
  • Food & beverage$7,61398%
  • Education$1011%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,765 in reported general payments places this provider in the 75th percentile of 21 neurology providers in Alaska.

See all neurology providers in Alaska

Medicare billing

Part B allowed, 2024
$339,433
Medicare patients
355
Services billed
1,681

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VimpatLacosamide13$16,453
BriviactBrivaracetam15$12,315
Levetiracetam89$4,949
Lacosamide16$3,156
Dalfampridine ErDalfampridine18$2,297
Modafinil13$1,233
Divalproex Sodium14$1,233
Zonisamide18$1,230
Oxcarbazepine24$1,112
Topiramate85$865
Divalproex Sodium ErDivalproex Sodium15$645
Donepezil Hcl29$352
Carbidopa-LevodopaCarbidopa/Levodopa32$300
Gabapentin20$248
Baclofen12$215

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
UCB, Inc.Vimpat, Briviact$497$28,76728 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 21 neurology providers in Alaska.

Other neurology in Wasilla

See the full list for Alaska

Where these figures come from

Is this you, or does something look wrong? →